Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RP42 homolog pseudogene (ENSG00000220695), also called RP42, is classified as a pseudogene, meaning it is a genomic DNA sequence similar to a known gene but rendered non-functional due to disabling mutations. Pseudogenes do not code for functional proteins and are not considered therapeutic targets[1][5]. Although some pseudogenes are transcribed as non-coding RNAs and may have roles in gene regulation or disease, there is no evidence this specific pseudogene is relevant as a biomarker or functional gene product[1][2][3][5]. RP42 homolog pseudogene is not a valid drug target, receptor, enzyme, transporter, or gene involved in known therapeutic pathways; it is a genomically disabled, non-coding copy and not functionally characterized[1][5].
None (not a druggable target)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RP42 homolog pseudogene (RP42).